Current antipsychotic drugs primarily target dopamine D2 receptors (D2Rs), in conjunction with other receptors such as those for serotonin. However, these drugs have serious side effects such as extrapyramidal symptoms (EPS) and diabetes. Identifying a specific D2R signaling pathway that could be targeted for antipsychotic effects, without inducing EPS, would be a significant improvement in the treatment of schizophrenia. We report here that the D2R forms a protein complex with Disrupted in Schizophrenia 1 (DISC1) that facilitates D2R-mediated glycogen synthase kinase (GSK)-3 signaling and inhibits agonist-induced D2R internalization. D2R-DISC1 complex levels are increased in conjunction with decreased GSK-3α/β (Ser21/9) phosphorylation in both postmortem brain tissue from schizophrenia patients and in Disc1-L100P mutant mice, an animal model with behavioral abnormalities related to schizophrenia. Administration of an interfering peptide that disrupts the D2R-DISC1 complex successfully reverses behaviors relevant to schizophrenia but does not induce catalepsy, a strong predictor of EPS in humans.
Cognitive dysfunction is a core feature of dementia and a prominent feature in
psychiatric disease. As non-redundant regulators of intracellular cAMP gradients,
phosphodiesterases (PDE) mediate fundamental aspects of brain function relevant to
learning, memory, and higher cognitive functions. Phosphodiesterase-4B (PDE4B) is an
important phosphodiesterase in the hippocampal formation, is a major Disrupted in
Schizophrenia 1 (DISC1) binding partner and is itself a risk gene for psychiatric
illness. To define the effects of specific inhibition of the PDE4B subtype, we
generated mice with a catalytic domain mutant form of PDE4B (Y358C) that has
decreased ability to hydrolyze cAMP. Structural modeling predictions of decreased
function and impaired binding with DISC1 were confirmed in cell assays. Phenotypic
characterization of the PDE4BY358C mice revealed facilitated
phosphorylation of CREB, decreased binding to DISC1, and upregulation of DISC1 and
β-Arrestin in hippocampus and amygdala. In behavioral assays,
PDE4BY358C mice displayed decreased anxiety and increased exploration,
as well as cognitive enhancement across several tests of learning and memory,
consistent with synaptic changes including enhanced long-term potentiation and
impaired depotentiation ex vivo. PDE4BY358C mice also
demonstrated enhanced neurogenesis. Contextual fear memory, though intact at
24 h, was decreased at 7 days in PDE4BY358C mice, an effect
replicated pharmacologically with a non-selective PDE4 inhibitor, implicating cAMP
signaling by PDE4B in a very late phase of consolidation. No effect of the
PDE4BY358C mutation was observed in the prepulse inhibition and forced
swim tests. Our data establish specific inhibition of PDE4B as a promising
therapeutic approach for disorders of cognition and anxiety, and a putative target
for pathological fear memory.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is conventionally considered a critical enzyme that involves in glycolysis for energy production. Recent previous studies have suggested that GAPDH is important in glutamate-induced neuronal excitotoxicity, while accumulated evidence also demonstrated that GAPDH nuclear translocation plays a critical role in cell death. However, the molecular mechanisms underlying this process remain largely unknown. In this study, we showed that GAPDH translocates to the nucleus in a Siah1-dependent manner upon glutamate stimulation. The nuclear GAPDH forms a protein complex with p53 and enhances p53 expression and phosphorylation. Disruption of the GAPDH-p53 interaction with an interfering peptide blocks glutamate-induced cell death and GAPDH-mediated up-regulation of p53 expression and phosphorylation. Furthermore, administration of the interfering peptide in vivo protects against ischemia-induced cell death in rats subjected to tMCAo. Our data suggest that the nuclear p53-GAPDH complex is important in regulating glutamate-mediated neuronal death and could serve as a potential therapeutic target for ischemic stroke treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.